Dexcom announces its first-ever over-the-counter CGM Stelo has been cleared by the FDA
Summary
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the U.S. Food and Drug Administration, and it will be available for purchase online this summer. They are primarily used by patients with diabetes since the information is wirelessly sent to a smartphone, which can help alert users, their families and their doctors to emergencies. Dexcoms new CGM is designed for patients with Type 2 diabetes who do not use insulin, and it is the first glucose biosensor that does not require a prescription, according to a release Tuesday. Jake Leach, chief operating officer at Dexcom, told CNBC in February that Stelo will have its own unique platform and branding. Dont miss these stories from CNBC PRO: • Instead of chasing Nvidia, investor buys these misunderstood, cheap growth stocks for big returns • Why Warren Buffett thinks the power of compound interest is the key to his success • Forget cash — its time to move into fixed income, Franklin Templeton strategist says • Dan Niles reveals why he prefers the Fantastic Four and when the AI bubble might pop • Investors should tread carefully in March after bitcoins explosive rally to $60,000
Classifications
AskAI Classifications
LabelsLinked Companies
